Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 77; no. 11; pp. 1284 - 1287
• Main Authors: Steiner, J, Bielau, H, Bernstein, H-G, Bogerts, B, Wunderlich, M T
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.11.2006; BMJ; BMJ Publishing Group LTD; BMJ Group
• Subjects: Adolescent; Adult; Age; analysis of variance; ANOVA; Biological and medical sciences; calcium-binding protein; Cerebrospinal fluid; CSF; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Enzyme-Linked Immunosorbent Assay; Female; GFAP; glial fibrillar acidic protein; Glial Fibrillary Acidic Protein - blood; Glial Fibrillary Acidic Protein - cerebrospinal fluid; Human viral diseases; Humans; Infectious diseases; Male; MBP; Medical sciences; Mental disorders; myelin basic protein; Myelin Basic Protein - blood; Myelin Basic Protein - cerebrospinal fluid; Nerve Growth Factors - blood; Nerve Growth Factors - cerebrospinal fluid; Neuroglia - metabolism; Neurology; neurone-specific enolase; Neurons - metabolism; NSE; Phosphopyruvate Hydratase - blood; Phosphopyruvate Hydratase - cerebrospinal fluid; Proteins; Psychopathology; S100 Calcium Binding Protein beta Subunit; S100 Proteins - blood; S100 Proteins - cerebrospinal fluid; S100B; Schizophrenia; Schizophrenia - physiopathology; Short Report; Statistical analysis; Variance analysis; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Germany; Psychosis; Nervous system diseases; Enzyme; Myelin; Basic protein; Schizophrenia; Lyases; Cerebrospinal fluid; Carbon-oxygen lyases; Release; Phosphopyruvate hydratase; Hydro-lyases
• ISSN: 0022-3050; 1468-330X
• DOI: 10.1136/jnnp.2006.093427

Objective: To assess levels of glial fibrillar acidic protein (GFAP), myelin basic protein (MBP), neurone-specific enolase (NSE) and S100B in patients with first-onset schizophrenia. Method: We investigated CSF and serum samples from 12 patients with first-onset schizophrenia and from 17 control subjects by ELISA (GFAP, MBP) or immunoluminometric sandwich assays (NSE, S100B). Results: Patients with schizophrenia had significantly higher levels of S100B in CSF (p = 0.004; 2.73 (SD 0.80) v 1.92 (0.58) μg/l) and serum (p = 0.032; 0.09 (0.03) v 0.08 (0.02) μg/l) in comparison with those in the matched control group. No diagnosis-dependent differences of protein concentration were seen for GFAP, MBP and NSE. Discussion: Our finding of increased levels of S100B in patients with schizophrenia without an indication for significant glial (GFAP, MBP) or neuronal (NSE) damage may be interpreted as indirect evidence for increased active secretion of S100B during acute psychosis.